{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:50:10Z","timestamp":1759333810921,"version":"build-2065373602"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Ganzhou Science and Technology Planning Project","award":["No. GZ2024YLJ016, GZ2024YLJ026, GZ2024ZSF064 and 2022-ZD1373"],"award-info":[{"award-number":["No. GZ2024YLJ016, GZ2024YLJ026, GZ2024ZSF064 and 2022-ZD1373"]}]},{"name":"the Science and Technology Program of the Health Commission of Jiangxi Province","award":["2025110045"],"award-info":[{"award-number":["2025110045"]}]},{"name":"the Clinical Research Center for Medical Imaging in Jiangxi Province","award":["No. 20223BCG7400199"],"award-info":[{"award-number":["No. 20223BCG7400199"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160330"],"award-info":[{"award-number":["82160330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Ganzhou Health Commission Scientific Research Planning Project","award":["GZWJW202402108"],"award-info":[{"award-number":["GZWJW202402108"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01922-8","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:50:32Z","timestamp":1759153832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomogram to predict the EGFR mutation status in stage III-IV solid lung adenocarcinoma patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Wenjian","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"10299","key":"1922_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"3","key":"1922_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1922_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","volume":"12","author":"E Castellanos","year":"2017","unstructured":"Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR -Mutated Non\u2013Small cell lung cancer. J Thorac Oncol. 2017;12(4):612\u201323.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1922_CR4","doi-asserted-by":"publisher","first-page":"e0228925","DOI":"10.1371\/journal.pone.0228925","volume":"15","author":"H-Y Yoon","year":"2020","unstructured":"Yoon H-Y, Ryu J-S, Sim YS, Kim D, Lee SY, Choi J, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. PLoS ONE. 2020;15(2):e0228925.","journal-title":"PLoS ONE"},{"issue":"18","key":"1922_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"Y-L Wu","year":"2020","unstructured":"Wu Y-L, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR -Mutated Non\u2013Small-Cell lung cancer. N Engl J Med. 2020;383(18):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"1922_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. J Thorac Oncol. 2018;13(3):323\u201358.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1922_CR7","first-page":"546","volume":"11","author":"G Zhang","year":"2021","unstructured":"Zhang G, Cao Y, Zhang J, Ren J, Zhao Z, Zhang X, et al. Predicting EGFR mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature. Am J Cancer Res. 2021;11(2):546\u201360.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"1922_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jtho.2016.02.010","volume":"11","author":"M Hasegawa","year":"2016","unstructured":"Hasegawa M, Sakai F, Ishikawa R, Kimura F, Ishida H, Kobayashi K. CT features of epidermal growth factor Receptor\u2013Mutated adenocarcinoma of the lung: comparison with nonmutated adenocarcinoma. J Thorac Oncol. 2016;11(6):819\u201326.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1922_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1148\/radiol.14140848","volume":"275","author":"C-M Choi","year":"2015","unstructured":"Choi C-M, Kim MY, Hwang HJ, Lee JB, Kim WS. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology. 2015;275(1):272\u20139.","journal-title":"Radiology"},{"key":"1922_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.lungcan.2018.06.030","volume":"123","author":"YJ Suh","year":"2018","unstructured":"Suh YJ, Lee H-J, Kim YJ, Kim KG, Kim H, Jeon YK, et al. Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study. Lung Cancer. 2018;123:52\u20139.","journal-title":"Lung Cancer"},{"key":"1922_CR11","doi-asserted-by":"publisher","first-page":"722106","DOI":"10.3389\/fonc.2021.722106","volume":"11","author":"W Chen","year":"2021","unstructured":"Chen W, Hua Y, Mao D, Wu H, Tan M, Ma W, et al. A computed Tomography-Derived radiomics approach for predicting uncommon EGFR mutation in patients with NSCLC. Front Oncol. 2021;11:722106.","journal-title":"Front Oncol"},{"issue":"3","key":"1922_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/1759-7714.12436","volume":"8","author":"J Zou","year":"2017","unstructured":"Zou J, Lv T, Zhu S, Lu Z, Shen Q, Xia L, et al. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I\/II l Ung adenocarcinoma. Thorac Cancer. 2017;8(3):260\u201370.","journal-title":"Thorac Cancer"},{"issue":"2","key":"1922_CR13","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.3747\/co.25.3805","volume":"25","author":"Y Cao","year":"2018","unstructured":"Cao Y, Xu H. A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma. Curr Oncol. 2018;25(2):e132\u20138.","journal-title":"Curr Oncol"},{"key":"1922_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2016.05.009","volume":"98","author":"J Dai","year":"2016","unstructured":"Dai J, Shi J, Soodeen-Lalloo AK, Zhang P, Yang Y, Wu C, et al. Air bronchogram: A potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules. Lung Cancer. 2016;98:22\u20138.","journal-title":"Lung Cancer"},{"issue":"1","key":"1922_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1148\/radiol.2016151455","volume":"280","author":"Y Liu","year":"2016","unstructured":"Liu Y, Kim J, Qu F, Liu S, Wang H, Balagurunathan Y, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology. 2016;280(1):271\u201380.","journal-title":"Radiology"},{"issue":"11","key":"1922_CR16","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.21037\/jtd.2018.10.19","volume":"10","author":"Q Lu","year":"2018","unstructured":"Lu Q, Ma Y, An Z, Zhao T, Xu Z, Chen H. Epidermal growth factor receptor mutation accelerates radiographic progression in lung adenocarcinoma presented as a solitary ground-glass opacity. J Thorac Dis. 2018;10(11):6030\u20139.","journal-title":"J Thorac Dis"},{"issue":"7","key":"1922_CR17","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ejso.2019.01.220","volume":"45","author":"N Miyahara","year":"2019","unstructured":"Miyahara N, Nii K, Benazzo A, Hoda MA, Iwasaki A, Klepetko W, et al. Solid predominant subtype in lung adenocarcinoma is related to poor prognosis after surgical resection: A systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(7):1156\u201362.","journal-title":"Eur J Surg Oncol"},{"key":"1922_CR18","doi-asserted-by":"publisher","first-page":"598721","DOI":"10.3389\/fonc.2020.598721","volume":"12","author":"B Zhang","year":"2021","unstructured":"Zhang B, Qi S, Pan X, Li C, Yao Y, Qian W, et al. Deep CNN model using CT radiomics feature mapping recognizes EGFR gene mutation status of lung adenocarcinoma. Front Oncol. 2021;12:10:598721.","journal-title":"Front Oncol"},{"key":"1922_CR19","doi-asserted-by":"crossref","unstructured":"Choe J, Lee SM, Kim W, Do K-H, Kim S, Choi S et al. CT radiomics-based prediction of anaplastic lymphoma kinase and epidermal growth factor receptor mutations in lung adenocarcinoma. Eur J Radiol. 2021;10.1016\/j.ejrad.2021.109710.","DOI":"10.1016\/j.ejrad.2021.109710"},{"issue":"11","key":"1922_CR20","doi-asserted-by":"publisher","first-page":"e1156","DOI":"10.1634\/theoncologist.2018-0706","volume":"24","author":"X Yang","year":"2019","unstructured":"Yang X, Dong X, Wang J, Li W, Gu Z, Gao D, et al. Computed Tomography-Based radiomics signature: A potential indicator of epidermal growth factor receptor mutation in pulmonary adenocarcinoma appearing as a subsolid nodule. Oncologist. 2019;24(11):e1156\u201364.","journal-title":"Oncologist"},{"issue":"1","key":"1922_CR21","doi-asserted-by":"publisher","first-page":"e13963","DOI":"10.1097\/MD.0000000000013963","volume":"98","author":"SR Digumarthy","year":"2019","unstructured":"Digumarthy SR, Padole AM, Gullo RL, Sequist LV, Kalra MK. Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? Med (Baltim). 2019;98(1):e13963.","journal-title":"Med (Baltim)"},{"issue":"4","key":"1922_CR22","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.21037\/tlcr-20-122","volume":"9","author":"G Liu","year":"2020","unstructured":"Liu G, Xu Z, Ge Y, Jiang B, Groen H, Vliegenthart R, et al. 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma. Transl Lung Cancer Res. 2020;9(4):1212\u201324.","journal-title":"Transl Lung Cancer Res"},{"key":"1922_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejrad.2019.01.005","volume":"112","author":"Y Chen","year":"2019","unstructured":"Chen Y, Yang Y, Ma L, Zhu H, Feng T, Jiang S, et al. Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma. Eur J Radiol. 2019;112:44\u201351.","journal-title":"Eur J Radiol"},{"issue":"2","key":"1922_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1183\/09031936.00010111","volume":"39","author":"N Girard","year":"2012","unstructured":"Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC-H, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012;39(2):366\u201372.","journal-title":"Eur Respir J"},{"issue":"6","key":"1922_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/RTI.0000000000000116","volume":"29","author":"J-S Hsu","year":"2014","unstructured":"Hsu J-S, Huang M-S, Chen C-Y, Liu G-C, Liu T-C, Chong I-W, et al. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging. 2014;29(6):357\u201363.","journal-title":"J Thorac Imaging"},{"issue":"2","key":"1922_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","volume":"16","author":"X Le","year":"2021","unstructured":"Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, et al. Dual EGFR-VEGF pathway inhibition: A promising strategy for patients with EGFR-Mutant NSCLC. J Thorac Oncol. 2021;16(2):205\u201315.","journal-title":"J Thorac Oncol"},{"key":"1922_CR27","doi-asserted-by":"publisher","first-page":"e18618","DOI":"10.7717\/peerj.18618","volume":"12","author":"J Hao","year":"2024","unstructured":"Hao J, Liu M, Zhou Z, Zhao C, Dai L, Ouyang S. Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels. PeerJ. 2024;12:e18618.","journal-title":"PeerJ"},{"issue":"1","key":"1922_CR28","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.tranon.2020.100954","volume":"14","author":"G Zhang","year":"2021","unstructured":"Zhang G, Zhang J, Cao Y, Zhao Z, Li S, Deng L, et al. Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma. Transl Oncol. 2021;14(1):100954.","journal-title":"Transl Oncol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01922-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01922-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01922-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:02:20Z","timestamp":1759190540000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01922-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01922-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"type":"electronic","value":"1471-2342"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board of Ganzhou People\u2019s Hospital (IRB no. TY-ZKY2024-104-01) approved the study and waived the requirement for written informed consent. All methods were carried out in accordance with Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"391"}}